MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC): from proof-of-concept to phase III trial (MAGRIT)
Keyword(s):
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 7501-7501
◽
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. TPS232-TPS232
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):